Oral anticoagulant therapy in older adults
Authors:
Open Access
- 14 April 2024
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 238, 1-10
Abstract
No abstract availableKeywords
This publication has 121 references indexed in Scilit:
- Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and MultimorbidityAdvances in Therapy, 2022
- Trends in Use of Oral Anticoagulants in Older Adults With Newly Diagnosed Atrial Fibrillation, 2010-2020JAMA Network Open, 2022
- Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous ThromboembolismJAMA, 2022
- Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and MultimorbidityAdvances in Therapy, 2021
- Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of HemorrhagePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
- Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor XaClinical Pharmacokinetics, 2015
- Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of ApixabanClinical Pharmacokinetics, 2015
- Polypharmacy is Associated with an Increased Risk of Bleeding in Elderly Patients with Venous ThromboembolismJournal of General Internal Medicine, 2014
- Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic ImpairmentClinical Pharmacokinetics, 2013
- Prevalence of Diagnosed Atrial Fibrillation in AdultsJAMA, 2001